These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 18236140)
21. Transdermal opioids for cancer pain. Cachia E; Ahmedzai SH Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999 [TBL] [Abstract][Full Text] [Related]
22. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Pergolizzi JV; Scholten W; Smith KJ; Leighton-Scott J; Willis JC; Henningfield JE Acta Anaesthesiol Taiwan; 2015 Jun; 53(2):71-6. PubMed ID: 26205326 [TBL] [Abstract][Full Text] [Related]
23. Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, pharmacodynamics and antinociceptive effects of buprenorphine following transdermal administration to horses. Nelson GR; Mama KR; Weiner D; McKemie DS; Kass PH; Steinmetz SJ; Knych HK Vet Anaesth Analg; 2024; 51(5):520-530. PubMed ID: 38834387 [TBL] [Abstract][Full Text] [Related]
25. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. Barutell C; Camba A; González-Escalada JR; Rodríguez M; Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364 [TBL] [Abstract][Full Text] [Related]
26. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Griessinger N; Sittl R; Likar R Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522 [TBL] [Abstract][Full Text] [Related]
28. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. Tschirner M; Ritzdorf I; Brünjes R MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217 [TBL] [Abstract][Full Text] [Related]
29. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Mitra F; Chowdhury S; Shelley M; Williams G Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402 [TBL] [Abstract][Full Text] [Related]
30. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Kögel B; Christoph T; Strassburger W; Friderichs E Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189 [TBL] [Abstract][Full Text] [Related]
31. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Christoph T; Kögel B; Schiene K; Méen M; De Vry J; Friderichs E Eur J Pharmacol; 2005 Jan; 507(1-3):87-98. PubMed ID: 15659298 [TBL] [Abstract][Full Text] [Related]
32. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884 [TBL] [Abstract][Full Text] [Related]
33. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018 [TBL] [Abstract][Full Text] [Related]
34. High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Buprenorphine Evaluation in Plasma-Application to Pharmacokinetic Studies in Rabbits. Tikhomirov M; Poźniak B; Śniegocki T Molecules; 2021 Jan; 26(2):. PubMed ID: 33467733 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. Steagall PV; Ruel HLM; Yasuda T; Monteiro BP; Watanabe R; Evangelista MC; Beaudry F BMC Vet Res; 2020 May; 16(1):154. PubMed ID: 32448336 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica). Thiede AJ; Garcia KD; Stolarik DF; Ma J; Jenkins GJ; Nunamaker EA J Am Assoc Lab Anim Sci; 2014 Nov; 53(6):692-9. PubMed ID: 25650977 [TBL] [Abstract][Full Text] [Related]
37. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Cichewicz DL; Welch SP; Smith FL Eur J Pharmacol; 2005 Nov; 525(1-3):74-82. PubMed ID: 16288738 [TBL] [Abstract][Full Text] [Related]
38. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O; Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. Andresen T; Upton RN; Foster DJ; Christrup LL; Arendt-Nielsen L; Drewes AM Basic Clin Pharmacol Toxicol; 2011 Apr; 108(4):274-84. PubMed ID: 21138531 [TBL] [Abstract][Full Text] [Related]
40. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Kress HG Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]